2022
End-of-life care trajectories among older adults with lung cancer
Davidoff AJ, Canavan ME, Prsic E, Saphire M, Wang SY, Presley CJ. End-of-life care trajectories among older adults with lung cancer. Journal Of Geriatric Oncology 2022, 14: 101381. PMID: 36202695, PMCID: PMC9974538, DOI: 10.1016/j.jgo.2022.09.010.Peer-Reviewed Original ResearchConceptsCancer-directed therapyLung cancerCare trajectoriesOlder adultsSupportive care servicesSEER-Medicare dataSkilled nursing facilitiesNon-Hispanic whitesRace/ethnicityCancer decedentsSymptom managementIntensive careOlder decedentsConcurrent careHospice careReferral regionsHigh riskMultinomial logistic regressionNursing facilitiesMedicare decedentsCare servicesLogistic regressionCancerHospiceDecedents
2020
End-of-life (EOL) trajectories among older adults dying with lung cancer (LC).
Davidoff A, Canavan M, Wang S, Prsic E, Saphire M, Presley C. End-of-life (EOL) trajectories among older adults dying with lung cancer (LC). Journal Of Clinical Oncology 2020, 38: e24008-e24008. DOI: 10.1200/jco.2020.38.15_suppl.e24008.Peer-Reviewed Original ResearchPalliative care servicesHospital referral regionsLung cancerCancer decedentsCare intensityNon-Hispanic whitesCD careLine therapyHospice enrollmentSEER-MedicareIntensive careHospice useOlder decedentsPhysician preferenceHigh riskHospice careMultinomial logistic regressionReferral regionsMedicare decedentsHigher ageCare servicesHealth statusLogistic regressionDecedentsHospiceThe association between initial chemotherapy treatment timing, intensity, and end-of-life (EOL) care trajectory among older adults with advanced stage lung cancer (aLC).
Presley C, Shahzad H, Canavan M, Prsic E, Saphire M, Wang S, Davidoff A. The association between initial chemotherapy treatment timing, intensity, and end-of-life (EOL) care trajectory among older adults with advanced stage lung cancer (aLC). Journal Of Clinical Oncology 2020, 38: e24009-e24009. DOI: 10.1200/jco.2020.38.15_suppl.e24009.Peer-Reviewed Original ResearchAdvanced-stage lung cancerDoublet chemotherapyEOL groupOlder adultsIntensity groupInitial chemotherapy regimenInitial chemotherapy treatmentPlatinum-based doubletsPlatinum-doublet chemotherapyFirst-line therapyUse of chemotherapyMajority of patientsEOL care preferencesStage lung cancerMain outcome measuresNon-Hispanic whitesMedicare registryChemotherapy regimenLine therapyCisplatin chemotherapyLung cancerChemotherapy treatmentAge 66Outcome measuresCare trajectories
2019
Patterns of palliative symptom management (PSM) medication use at end-of-life (EoL) among Medicare beneficiaries with advanced lung cancer (advLC).
Davidoff A, Prsic E, Saphire M, Canavan M, Wang S, McCorkle R, Presley C. Patterns of palliative symptom management (PSM) medication use at end-of-life (EoL) among Medicare beneficiaries with advanced lung cancer (advLC). Journal Of Clinical Oncology 2019, 37: 130-130. DOI: 10.1200/jco.2019.37.27_suppl.130.Peer-Reviewed Original ResearchMedication useEoL-1Medication receiptPoor patient-provider communicationAdvanced lung cancerHigh symptom burdenPatient demographic characteristicsPatient-provider communicationAge 77 yearsMedicare/MedicaidRace/ethnicity groupsNon-Hispanic whitesNausea/ vomitingSymptom burdenHospice enrollmentSymptom reliefConcurrent radiationSEER-MedicareOutpatient settingParenteral medicationsLung cancerMedicare beneficiariesPatientsLogistic regressionOlder adults